affiliated companies 0.9 - - 0.9
Income from continuing
operations $53.0 ($1.6) ($0.8) $50.6
Net income per diluted share:
Continuing operations $1.51 ($0.04) ($0.02) $1.45
Please refer to the "Notes to Non-GAAP financial measures" for more
information. Non-GAAP measures are intended to explain or aid in the use of, not as a
substitute for, the related GAAP financial measure.
West Pharmaceutical Services, INC.
SUPPLEMENTAL INFORMATION AND NOTES TO NON-GAAP FINANCIAL MEASURES
For additional details, please see the attached financial schedules and Safe Harbor Statement.
For the purpose of aiding the comparison of our year-to-year results, reference is made in this release and may be made in management commentary on the release, to results excluding certain items in an effort to improve the analysis of underlying trends in the financial statements, and for consistency with performance metrics used for incentive compensation programs. These re- measured period results are not in conformity with United States generally accepted accounting principles ("GAAP") and are "non-GAAP financial measures." The non-GAAP financial measures are intended to explain or aid in the use of, not as a substitute for, the related GAAP financial measures.
(1) "Adjusted operating profit" and its components and "adjusted
diluted earnings per share (EPS)," both of which are non-GAAP financial
measures, are defined as reported operating profit and reported diluted EPS
excluding the impact of the 2008 Restructuring Charges, the 2008 Contract
Settlement gain, and the 2008 and 2007 Income Tax Adjustments, as described
below. Reconciliations of the non-GAAP financial measures to the most
comparable financial results prepared in conformity to GAAP are provided
|SOURCE West Pharmaceutical Services, Inc.|
Copyright©2008 PR Newswire.
All rights reserved